November 1, 2017 / 3:53 PM / a month ago

Fitch Affirms GSK at 'A'; Stable Outlook

(The following statement was released by the rating agency) LONDON, November 01 (Fitch) Fitch Ratings has affirmed UK-based pharmaceuticals company GlaxoSmithKline PLC's (GSK) Long-Term Issuer Default Rating (IDR) at 'A' with Stable Outlook. Fitch has also affirmed the senior unsecured rating at 'A' for the debt issued by GlaxoSmithKline PLC, GlaxoSmithKline Capital PLC, and GlaxoSmithKline Capital Inc. The affirmation reflects Fitch's expectation that GSK's leverage should remain at the top end compatible with its rating. At the same time, Fitch recognises that GSK has significant financial flexibility and various strategic options including possible divestments, changes in its capital allocation policy and the structuring of potential acquisitions. Moreover, the current 'A' rating is supported by GSK's scale, good geographical diversification, and range of treatment areas relative to sector peers. KEY RATING DRIVERS Pressure on FY18 Margins: Fitch expects a robust performance for the financial year to December 2017 (FY17) to be followed by a transitional year in which FFO is likely to decline due to the lower profitability of the pharma division. Our expectation of lower FY18 pharma margins is based on the likely entry of generic competition in the US for its highly profitable drug Advair (11% of global LTM September 2017 sales), the patent expiration of Avodart in the EU (2% of global LTM sales to September 17), ongoing pricing pressure affecting the rest of its respiratory portfolio, the launch by Gilead of a competing HIV drug the slowing down growth of its HIV franchise, and by continuing investments in recently launched drugs. Slight Recovery in FY19: Fitch anticipates a modest recovery in profit margins in FY19 and FY20 driven by restructuring efforts in its Consumer Health division and a slight recovery in pharma margins as recently launched drugs mature. Reduced Rating Headroom from FY18: Fitch anticipates that FFO adjusted net leverage could approach 3.0x in FY18 due to the decline in FFO driven by lower pharma margins. Fitch's base-case forecast is that net leverage will stay around the 3.0x level over the rating horizon despite a recovery in margins and low-single-digit revenue growth. This is based on Fitch's expectation of a continuation of GSK's generous dividend policy leading to slightly negative FCF generation from 2018 onwards, and Fitch's assumption that Novartis' put option will be exercised in FY18 and settled by GSK in equal instalments over a four-year period. M&A Ambitions: The value of Novartis' stake is assumed at GBP8.5 billion, in line with GSK's balance sheet provision in 3Q17. Management has stated its intention to increase the scale of its Consumer Healthcare business through acquisitions, but Fitch would treat any additional medium-size or large acquisition, including a potential obligation to buy out Pfizer's 12% stake in its ViiV business, as event risk. Significant Financial Flexibility: GSK has a high degree of flexibility with regard to some of the negative drivers for the financial risk profile, particularly with regard to the generous shareholder remuneration, the timing and structure of the exit of minorities and of potential acquisitions, and possible divestments of non-core assets and partial IPOs of businesses. Strong Market Position and Diversification: GSK operates a diversified business model spanning a broad portfolio of treatment areas, with industry-leading positions in respiratory, HIV, vaccines and consumer-healthcare products. GSK also enjoys a diversified geographical mix with and an industry-leading presence in emerging markets. As part of its recent portfolio reorganisation, GSK exited the increasingly competitive oncology treatment area to concentrate on its enlarged vaccines and consumer-health operations, which Fitch expects will benefit from economies of scale and growth opportunities in developing markets. Positive Sector Trends: Fitch views certain secular trends in the pharma- and healthcare sectors as positive, with increasing access to healthcare globally, an ageing population, an increase in chronic diseases, as well as innovation in specialist treatments. Nevertheless, the focus on delivering value to patients and healthcare systems will accelerate the industry-wide review of pricing models in favour of performance-based pay. Fitch however believes that truly innovative and differentiated drugs will continue to attract premium prices and good market access as evidenced by GSK's strong growth of its anti-viral business. DERIVATION SUMMARY GSK's rating of 'A' remains well positioned in the global pharma universe, with a similar size compared to its higher-rated peer Sanofi (AA-/Negative) and with scale advantages over UK peer AstraZeneca (A-/Negative). GSK's EBITDA and FFO margins are in line with its UK peer AstraZeneca and its American peer Eli Lilly (A/Stable), lower than those of higher-rated peers Roche (AA/Stable), Novartis (AA/Negative), Sanofi (AA-/Negative) and Pfizer (A+/Negative), and stronger than those of its European peer Bayer (A/RWN). Its financial profile has improved in FY16 and FY17 YTD. Its FFO adjusted net leverage is now in line with that of American peers Pfizer (A+/Negative), and Merck & Co (A/Stable), but still higher than higher-rated European peers. Its FFO fixed charge coverage is lower than that of other 'A' and 'A+' rated pharma peers. GSK's slightly negative FCF generation caused by its generous dividend policy is unusual in the 'A' category and compares negatively with the FCF generation of other European and American pharma peers in the 'A' category. KEY ASSUMPTIONS Fitch's key assumptions within our rating case for the issuer are listed below. - Fitch expects revenue growth to slow down between FY18-22 projecting an average sales growth of 2.5% (after sales growth expected to reach around 8% in FY17). We expect positive growth effects from new product launches to be counterbalanced by increasing biosimilar competition for GSK's key drug Advair. We expect pressure on GSL's profitability to increase, modelling a group EBITDA margin of just below/around 27% over the period FY18-FY20, caused by increasing competition and pricing pressure for some of GSK's key drugs. - Pharma R&D expense (excl. Consumer Health) modelled at unchanged level of around 15% of pharma-only sales. - Moderate working-capital outflows in line with sales growth. - Stable dividend until 2020, causing slightly negative FCF generation over the four-year rating horizon. - Bolt-on acquisitions to be financed with disposal of non-core businesses. - Consumer healthcare put option exercised by Novartis in FY18, but paid for by GSK in four equivalent yearly instalments. No buyout of the ViiV minorities over the four-year rating horizon. This buyout or indeed any other large scale M&A would be treated as event risk. RATING SENSITIVITIES Future Developments That May, Individually or Collectively, Lead to Negative Rating Action - Inability to defend its top-line growth and its profitability following the expiration of key products and despite restructuring efforts - Major debt-financed acquisitions, share buybacks and/or minority payouts, which result in FFO adjusted net leverage above 3.0x on a continuing basis - FFO fixed charge cover below 5.0x on a continuing basis - FFO/sales below 20% and continued negative FCF driving a weakening of debt protection ratios Future Developments That May, Individually or Collectively, Lead to Positive Rating Action Fitch views an upgrade to 'A+' unlikely over the rating horizon. However future developments that may, individually or collectively, lead to positive rating action include: - successful product launches leading to a stable, predictable top-line performance and sustainable improvement in profitability; - capital allocation and financial policies in line with a higher rating level, including shareholder returns, M&A and payouts to minorities; - FFO adjusted net leverage trending towards 2.0x and FFO net fixed charge cover above 8x on a continuing basis; - FFO/sales above 25% and FCF/sales in the mid-single digits. LIQUIDITY Adequate Liquidity: At FYE16 GSK had readily available cash (as defined by Fitch) of GBP4.5 billion and undrawn committed credit facilities of GBP4.4 billion, which covered the GBP4.1 billion of short-term debt. By September 2017 GBP2.2 billion of this short-term debt due in 2017 has been already refinanced. Undrawn credit facilities included a GBP1.9 billion committed facility maturing in in September 2021 and a USD2.5 billion 364-day facility. In addition, GSK has a USD10 billion (GBP8.1 billion) US commercial paper programme, from which USD1.4 billion had been issued in December 2016. FULL LIST OF RATING ACTIONS GlaxoSmithKline PLC -Long-Term IDR: affirmed at 'A'; Stable Outlook -Senior unsecured debt: affirmed at 'A' GlaxoSmithKline Capital Inc. -Senior unsecured debt: affirmed at 'A' GlaxoSmithKline Capital PLC -Senior unsecured debt: affirmed at 'A' Contact: Principal Analyst Xavier Taule Flores Analyst +34 93492 9513 Supervisory Analyst Frank Orthbandt Director +44 20 3530 1037 Fitch London 30 North Colonnade London E14 5GN Committee Chairperson Giulio Lombardi Senior Director +39 02 8790 87214 Summary of Financial Statement Adjustments Fitch adjusts its debt by capitalising annual lease payments using the factor 8x. We also adjust Readily Available Cash by GBP600 million for legally restricted cash/cash in transit, working capital absorption and short-term investments with a maturity greater than three months. Media Relations: Adrian Simpson, London, Tel: +44 203 530 1010, Email: adrian.simpson@fitchratings.com. Additional information is available on www.fitchratings.com. For regulatory purposes in various jurisdictions, the supervisory analyst named above is deemed to be the primary analyst for this issuer; the principal analyst is deemed to be the secondary. Applicable Criteria Corporate Rating Criteria (pub. 07 Aug 2017) here Additional Disclosures Dodd-Frank Rating Information Disclosure Form here Solicitation Status here#solicitation Endorsement Policy here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: here. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEB SITE AT WWW.FITCHRATINGS.COM. PUBLISHED RATINGS, CRITERIA, AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE, AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE CODE OF CONDUCT SECTION OF THIS SITE. DIRECTORS AND SHAREHOLDERS RELEVANT INTERESTS ARE AVAILABLE here. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE. Copyright © 2017 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved. In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch’s factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third- party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of Fitch’s ratings and reports should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings and forecasts of financial and other information are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings and forecasts can be affected by future events or conditions that were not anticipated at the time a rating or forecast was issued or affirmed. The information in this report is provided “as is” without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch are based on established criteria and methodologies that Fitch is continuously evaluating and updating. Therefore, ratings and reports are the collective work product of Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ratings may be changed or withdrawn at any time for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US$1,000 to US$750,000 (or the applicable currency equivalent) per issue. In certain cases, Fitch will rate all or a number of issues issued by a particular issuer, or insured or guaranteed by a particular insurer or guarantor, for a single annual fee. Such fees are expected to vary from US$10,000 to US$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction. Due to the relative efficiency of electronic publishing and distribution, Fitch research may be available to electronic subscribers up to three days earlier than to print subscribers. For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below